Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension
This article was originally published in The Pink Sheet Daily
Executive Summary
The first-in-class drug will launch later in March.
You may also be interested in...
Novartis Plans To Buy Back Speedel For $880 Million
Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.
Novartis Plans To Buy Back Speedel For $880 Million
Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.
Tekturna Shows Non-Inferiority To Merck’s Cozaar On Left Ventricular Hypertrophy
Combination of both medicines, however, did not achieve a statistically significant reduction in LVH over losartan alone.